Insys IPO prices low; Ambit and Alcobra set terms
This article was originally published in Scrip
Executive Summary
Insys Therapeutics priced its initial public offering at $8 per share – half of the $16 to $18 range the company revealed for its 4 million shares in mid-April – but saw a respectable boost by the end of its first trading day on 2 May to $9.50.